



EOS imaging Invited to Present at Three Upcoming U.S. Investor Conferences

PARIS, March 6, 2014 – EOS imaging (NYSE Euronext, FR0011191766 – EOSI), the pioneer in orthopaedic 2D/3D imaging, announced today that Marie Meynadier, Chief Executive Officer, has been invited to participate in three upcoming U.S. investor conferences in March and April. The first conference is the Canaccord Genuity Musculoskeletal Conference in New Orleans, LA.

Event: Canaccord Genuity Musculoskeletal ConferenceDate: Tuesday, March 11, 2014Time: 9:40 a.m. CT / 10:40 a.m. ET

The second conference is the BTIG Inaugural Snowbird Medical Technology, Diagnostics, and Healthcare IT Conference in Snowbird, UT. This conference will allow institutional investors to meet with the Company but does not include a formal presentation.

Event: BTIG Inaugural Snowbird Medical Technology, Diagnostics, and Healthcare IT ConferenceDate: March 18-20, 2014

The third conference is the 13th Annual Needham Healthcare Conference in New York, NY.

Event: 13th Annual Needham Healthcare ConferenceDate: Wednesday, April 9, 2014Time: 12:30 p.m. ET

A live webcast of the presentations at the Canaccord Genuity Musculoskeletal Conference and the Needham Healthcare Conference will be available on EOS imaging's website at www.eos-imaging.com. A replay of the webcasts will be available for 90 days after the date of the presentation.

About EOS imaging:

EOS imaging designs, develops, and markets EOS[®], a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market the system in 31 countries, including the United States (FDA), Japan, Canada, Australia and the European Union (EU). Backed by an installed base of 75 sites and more than 400,000 imaging sessions, EOS[®] benefits from worldwide recognition within the global medical community. As of December 31, 2013 the Group posted 2013 consolidated revenue of €15.2 million and employed 102 people including an R&D team of 38 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), in Montreal (Canada) and Frankfurt (Germany), and offices in Singapore. For further information, please visit www.eos-imaging.com





3D orthopaedic imaging, see better to treat better



DON'T GUESS. **SEE.**



EOS imaging is listed on Compartment C of the NYSE Euronext Paris ISIN: FR0011191766 - Ticker: EOSI

Contacts:

Anne Renevot

CFO Tel.: +33 (0)1 55 25 61 24 <u>investors@eos-imaging.com</u>

NewCap

Financial communication and investor relations Sophie Boulila / Pierre Laurent Tel.: +33 (0)1 44 71 94 91 - <u>eosimaging@newcap.fr</u>

The Ruth Group (US)

Press relations Melanie Sollid-Penton Ph: 646-536-7023 <u>msollid@theruthgroup.com</u>